Apellis (APLS) | Financial Analysis & Statements
Apellis Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
199.9M
Gross Profit
170.2M
85.13%
Operating Income
-51.1M
-25.58%
Net Income
-59.0M
-29.49%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
705.1M
Shareholders Equity
370.1M
Debt to Equity
1.90
Cash Flow Metrics
Operating Cash Flow
-49.5M
Free Cash Flow
-14.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Apellis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.0B | 781.4M | 396.6M | 75.4M | 66.6M |
| Cost of Goods Sold | 102.2M | 117.7M | 58.5M | 5.6M | 5.2M |
| Gross Profit | 901.5M | 663.6M | 338.1M | 69.8M | 61.4M |
| Gross Margin % | 89.8% | 84.9% | 85.2% | 92.5% | 92.2% |
| Operating Expenses | |||||
| Research & Development | 295.9M | 327.6M | 354.4M | 387.2M | 420.9M |
| Selling, General & Administrative | 550.3M | 501.1M | 500.8M | 277.2M | 176.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 846.1M | 828.6M | 855.2M | 664.4M | 597.6M |
| Operating Income | 55.4M | -165.0M | -517.1M | -594.6M | -536.3M |
| Operating Margin % | 5.5% | -21.1% | -130.4% | -788.4% | -805.7% |
| Non-Operating Items | |||||
| Interest Income | 13.1M | 12.8M | 20.9M | 8.9M | 418.0K |
| Interest Expense | 44.3M | 40.4M | 29.6M | 32.6M | 13.2M |
| Other Non-Operating Income | -133.0K | -4.1M | -727.0K | -33.2M | -196.9M |
| Pre-tax Income | 24.1M | -196.7M | -526.5M | -651.5M | -746.0M |
| Income Tax | 1.7M | 1.2M | 2.1M | 669.0K | 352.0K |
| Effective Tax Rate % | 7.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 22.4M | -197.9M | -528.6M | -652.2M | -746.4M |
| Net Margin % | 2.2% | -25.3% | -133.3% | -864.7% | -1,121.3% |
| Key Metrics | |||||
| EBITDA | 70.0M | -152.6M | -495.2M | -584.5M | -533.0M |
| EPS (Basic) | $0.18 | $-1.60 | $-4.45 | $-6.15 | $-8.84 |
| EPS (Diluted) | $0.18 | $-1.60 | $-4.45 | $-6.15 | $-8.84 |
| Basic Shares Outstanding | 126145000 | 123905000 | 118678000 | 106114000 | 84421000 |
| Diluted Shares Outstanding | 126145000 | 123905000 | 118678000 | 106114000 | 84421000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Apellis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 466.2M | 411.3M | 351.2M | 551.8M | 640.2M |
| Short-term Investments | - | - | - | 0 | 60.4M |
| Accounts Receivable | 366.2M | 264.9M | 206.4M | 7.7M | 10.1M |
| Inventory | 142.6M | 81.4M | 146.4M | 85.7M | 16.3M |
| Other Current Assets | 1.6M | 4.8M | 4.4M | 6.5M | 70.7M |
| Total Current Assets | 1.0B | 789.0M | 766.3M | 719.5M | 824.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 19.9M | 19.0M | 21.1M | 24.9M | 26.1M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 40.5M | 77.1M | 1.3M | 15.8M | 31.6M |
| Total Non-Current Assets | 60.4M | 96.1M | 22.4M | 40.7M | 57.7M |
| Total Assets | 1.1B | 885.1M | 788.7M | 760.2M | 881.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 56.8M | 38.6M | 37.5M | 37.3M | 16.9M |
| Short-term Debt | 100.7M | 6.8M | 6.4M | 5.6M | 4.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 75.8M | 29.5M | 7.6M |
| Total Current Liabilities | 323.6M | 185.5M | 247.6M | 167.6M | 131.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 373.6M | 463.0M | 104.5M | 107.1M | 206.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 7.9M | 8.0M | 242.1M | 315.6M | 345.2M |
| Total Non-Current Liabilities | 381.5M | 471.0M | 346.6M | 422.7M | 551.3M |
| Total Liabilities | 705.1M | 656.5M | 594.2M | 590.3M | 683.1M |
| Equity | |||||
| Common Stock | 12.0K | 12.0K | 12.0K | 11.0K | 10.0K |
| Retained Earnings | -3.0B | -3.0B | -2.8B | -2.3B | -1.7B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 370.1M | 228.5M | 194.5M | 169.9M | 198.7M |
| Key Metrics | |||||
| Total Debt | 474.4M | 469.8M | 110.9M | 112.7M | 210.2M |
| Working Capital | 691.2M | 603.4M | 518.7M | 551.9M | 692.2M |
Balance Sheet Composition
Apellis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 22.4M | -197.9M | -528.6M | -652.2M | -746.4M |
| Depreciation & Amortization | 1.6M | 1.8M | 1.7M | 1.5M | 1.5M |
| Stock-Based Compensation | 104.0M | 114.1M | 105.9M | 91.1M | 70.7M |
| Working Capital Changes | -102.4M | -56.9M | -233.2M | 2.1M | -69.6M |
| Operating Cash Flow | 28.0M | -128.4M | -627.9M | -528.8M | -737.5M |
| Investing Activities | |||||
| Capital Expenditures | -313.0K | -403.0K | -674.0K | -1.5M | -1.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | 0 | -331.9M | -171.3M |
| Investment Sales | - | 0 | 0 | 393.3M | 420.0M |
| Investing Cash Flow | -313.0K | -403.0K | -674.0K | 59.9M | 247.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 365.5M | - | 0 | 0 |
| Debt Repayment | - | - | - | - | 0 |
| Financing Cash Flow | -11.0K | 130.4M | 317.8M | 339.9M | 374.6M |
| Free Cash Flow | 45.0M | -88.3M | -595.5M | -515.3M | -564.2M |
| Net Change in Cash | 27.7M | 1.6M | -310.8M | -129.0M | -115.3M |
Cash Flow Trend
Apellis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
227.44
Forward P/E
-167.62
Price to Book
14.01
Price to Sales
5.21
PEG Ratio
-167.62
Profitability Ratios
Profit Margin
2.23%
Operating Margin
-25.58%
Return on Equity
7.48%
Return on Assets
3.53%
Financial Health
Current Ratio
3.14
Debt to Equity
128.15
Beta
-0.20
Per Share Data
EPS (TTM)
$0.18
Book Value per Share
$2.92
Revenue per Share
$7.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| APLS | 5.2B | 227.44 | 14.01 | 7.48% | 2.23% | 128.15 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






